Navigation Links
Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada
Date:3/3/2009

Clive V. Bennett is Named as the President and CEO of the New Canadian Entity

WHIPPANY, N.J., March 3 /PRNewswire/ -- Halo Pharmaceutical, a privately held specialty pharmaceutical company, has announced today that it is establishing a Canadian subsidiary to be called Halo Pharmaceutical Marketing (Canada) Ltd. This company will have its headquarters in Ontario, Canada, and its main purpose will be the marketing, sale and distribution of branded pharmaceutical products currently available in other major markets but not marketed in Canada. Halo is seeking, evaluating, and moving forward with opportunities for in-licensing and for the acquisition of branded products for both the US and Canadian markets from companies looking to rationalize their product portfolios. The Canadian subsidiary will be structured as a joint venture with CB&A Inc., a Canadian entity also based in Ontario, Canada. "We are excited about the opportunity to market a number of products in Canada as we continue to grow our North American business," commented Mohd Asif, Chief Financial Officer of Halo Pharmaceutical.

Halo has also named Clive V. Bennett as the President and CEO of this Canadian entity. Mr. Bennett, a Canadian pharmaceutical executive has over 38 years of experience in the global pharmaceutical industry. Prior to joining Halo Mr. Bennett worked for Patheon Inc for seven years. He held various top level positions at Patheon including the roles of Chief Scientific Officer, President of Patheon USA and President of Mova Pharmaceutical, a subsidiary of Patheon. Prior to his career at Patheon Mr. Bennett was Executive VP and Head of Global Operations for Hoechst Marion Roussel headquartered in Frankfurt, Germany.

"Some of the products we are intending to launch in the Canadian market can make a valuable contribution to the country's healthcare. I am looking forward to driving that effort on behalf of Halo," said Clive Bennett.

"We are glad to have someone of Clive's stature and ability working with us and helping us to grow our North American branded pharmaceutical business," said Al Rosenston, VP of Business Development for Halo.

About Halo Pharmaceutical:

Halo Pharmaceutical, headquartered in Whippany, NJ, is a specialty pharmaceutical company engaged in pharmaceutical branded product lifecycle management. Halo also offers full service state-of-the-art contract manufacturing, formulation development and laboratory testing services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ Chicago , ... local organizations: North Chicago Animal Control and Friends and Our House of Hope Rescue. ... and trained volunteers who support rescued animals held in the City of North Chicago’s ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher ... year. We would all agree of course–no time of year is a good time ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and ... infusion services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, ... "As we continue to build on ...
(Date:12/7/2016)... RIDGEFIELD, Conn. , Dec. 7, 2016 According ... survey, in more than one-third (38%) of patients with non-small ... their epidermal growth factor receptor (EGFR) genetic mutation status. The ... abstract ( LBA ID #6067 #P3.02b ) at ... Vienna, Austria . The survey results ...
(Date:12/7/2016)... PUNE, India , December 7, 2016 According ... Component (Services, Software), Delivery Mode, Product Type (Integrated, Standalone), Model (Knowledge-Based), Type ... by MarketsandMarkets, The CDSS Market is expected to reach USD 1,519.2 Million ... 12.2%. Continue Reading ... ...
Breaking Medicine Technology: